Vardenafil FAQs
Tetrabenazine: (Major) Concomitant use of vardenafil and tetrabenazine increases
Overdose/Missed Dose
Ritlecitinib: (Major) Do not use vardenafil orally disintegrating tablets with ritlecitinib due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A; ritlecitinib is a moderate levitra price list CYP3A inhibitor. Ritonavir: (Major) Do not use vardenafil orally disintegrating tablets with ritonavir due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 72-hour period of vardenafil oral tablets. Romidepsin: (Moderate) Concomitant use of vardenafil and romidepsin may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Sapropterin: (Moderate) Sapropterin acts as a cofactor in the synthesis of nitric oxide and may cause vasorelaxation.
What conditions is Stendra approved to treat?
Caution should be exercised when administering sapropterin in combination with drugs that affect nitric oxide-mediated vasorelaxation such as phosphodiesterase inhibitors. When given together these agents may produce an additive reduction in blood pressure. The combination of sapropterin and a phosphodiesterase (PDE5) inhibitor did not significantly reduce blood pressure when administered concomitantly in animal studies. The additive effect of these agents has not been studied in humans. Saquinavir: (Contraindicated) Coadministration of saquinavir boosted with ritonavir is contraindicated with other drugs that may prolong the QT interval and which are primary CYP3A4 substrates, such as vardenafil. the risk of QT/QTc prolongation and torsade de pointes (TdP).
| Parameter | Value | Notes |
|---|---|---|
| Onset of Action | 25-60 minutes | Typically 30-45 minutes |
| Duration of Effect | Up to 5 hours | Varies with dose and individual |
| Half-life | Approximately 4-5 hours | Determines dosing frequency |
| Time to Peak Concentration | About 60 minutes | After oral administration |
Thioridazine: (Contraindicated) Avoid concomitant use of vardenafil and thioridazine due to
| Medication | Active Ingredient | Onset of Action | Duration | Typical Dose | Cost |
|---|---|---|---|---|---|
| Vardenafil (Levitra) | Vardenafil | 25-60 min | Up to 5 hours | 10 mg | Moderate |
| Sildenafil (Viagra) | Sildenafil | 30-60 min | 4-6 hours | 50 mg | Moderate |
| Tadalafil (Cialis) | Tadalafil | 30-60 min | Up to 36 hours | 10-20 mg | Higher |
an increased risk for torsade de pointes (TdP) and QT/QTc prolongation.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Levitra Original | 20mg | 8 Pills | 65.05€ 61.95€ | |
| Levitra Original | 20mg | 48 + 4 Pills | 235.14€ 223.94€ | |
| Levitra Generic | 40mg | 10 Pills | 41.37€ 39.40€ | |
| Levitra Generic | 10mg | 30 + 4 Pills | 62.39€ 59.42€ | |
| Levitra Generic | 20mg | 360 + 10 Pills | 458.44€ 436.61€ | |
| Levitra Generic | 20mg | 120 + 10 Pills | 224.15€ 213.48€ | |
| Levitra Generic | 60mg | 270 + 10 Pills | 714.53€ 680.50€ | |
| Levitra Generic | 40mg | 180 + 10 Pills | 405.06€ 385.77€ | |
| Levitra Generic | 60mg | 180 + 10 Pills | 501.43€ 477.55€ | |
| Levitra Soft Tabs | 20mg | 20 Pills | 74.68€ 71.12€ | |
| Levitra Generic | 20mg | 30 + 4 Pills | 70.59€ 67.23€ | |
| Levitra Generic | 20mg | 60 + 6 Pills | 131.11€ 124.87€ |
Tipranavir: (Major) Do not use vardenafil orally disintegrating
How RedBox Rx can help
Tacrolimus: (Moderate) Concomitant use of vardenafil and tacrolimus may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Tamoxifen: (Moderate) Concomitant use of tamoxifen and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Tamsulosin: (Moderate) Due to the potential for symptomatic hypotension, patients should be stable on tamsulosin therapy before initiating therapy with the lowest dose of vardenafil. Telavancin: (Moderate) Concomitant use of vardenafil and telavancin may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Terazosin: (Moderate) Due to the potential for symptomatic hypotension, patients should be stable on alpha-blocker therapy before initiating therapy with the lowest dose of vardenafil. tablets with tipranavir boosted with ritonavir due to increased
Study design
Sotalol: (Major) Concomitant use of vardenafil and sotalol increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Stiripentol: (Moderate) Consider a dose adjustment of vardenafil when coadministered with stiripentol. Coadministration may alter plasma concentrations of vardenafil resulting in an increased risk of adverse reactions and/or decreased efficacy. In vitro data predicts inhibition or induction of CYP3A4 by stiripentol potentially resulting in clinically significant interactions. Sunitinib: (Moderate) Concomitant use of vardenafil and sunitinib may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. vardenafil exposure; do not exceed a single dose of
Prescription Status: Rx-Only vs. OTC
Posaconazole: (Contraindicated) The concurrent use of posaconazole with drugs that are associated with QT prolongation and are also CYP3A4 substrates, such as vardenafil, is contraindicated. Posaconazole is associated with QT prolongation, and vardenafil may cause QT prolongation at both therapeutic and supratherapeutic doses. Elevated plasma concentrations of vardenafil may also increase the risk for other vardenafil-related adverse events, such as prolonged erection or potential for syncope. Prazosin: (Moderate) Due to the potential for symptomatic hypotension, patients should be stable on alpha-blocker therapy before initiating therapy with the lowest dose of vardenafil. Primaquine: (Moderate) Concomitant use of vardenafil and primaquine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.
What should I do if I accidentally take too much vardenafil?
Procainamide: (Major) Vardenafil should be avoided in patients taking Class IA antiarrhythmics (disopyramide, procainamide, and quinidine). Prochlorperazine: (Minor) Use vardenafil with caution in combination with prochlorperazine due to increased risk of QT prolongation. Prochlorperazine is also associated with a possible risk for QT prolongation. Promethazine: (Moderate) Concomitant use of promethazine and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Promethazine; Dextromethorphan: (Moderate) Concomitant use of promethazine and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. 2.5 mg per 72-hour period of vardenafil oral tablets. Tolterodine: (Major) Due to the potential for QT prolongation and torsade
References (13)
Saquinavir boosted with ritonavir is a strong CYP3A4 inhibitor that increases the QT interval in a dose-dependent fashion. Selpercatinib: (Major) Concomitant use of vardenafil and selpercatinib increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Sertraline: (Moderate) Concomitant use of vardenafil and sertraline may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. The degree of QT prolongation associated with sertraline is not clinically significant when administered within the recommended dosage range; QT prolongation has been described at 2 times the maximum recommended dose. Silodosin: (Moderate) Due to the potential for symptomatic hypotension, patients should be stable on silodosin therapy before initiating therapy with the lowest dose of vardenafil.
How does Stendra help with these illnesses?
Conversely, patients already receiving an optimized dose of vardenafil should be started on the lowest dose of silodosin; increases in the alpha-blocker dose should be done in a stepwise fashion. Other variables, such as intravascular volume depletion, concurrent antihypertensive therapy, or evidence of hemodynamic instability with alpha-blocker monotherapy, may affect the safety of concomitant use of vardenafil and silodosin. Siponimod: (Major) Concomitant use of vardenafil and siponimod increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Sodium Stibogluconate: (Moderate) Concomitant use of sodium stibogluconate and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Solifenacin: (Moderate) Concomitant use of vardenafil and solifenacin may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. de pointes (TdP), caution is advised when administering tolterodine with vardenafil.
- Vardenafil requires a prescription; self-medicating is unsafe.
- Take Levitra approximately 60 minutes before intimacy.
- Do not take more than one dose per 24 hours.
- Symptoms like priapism need immediate medical attention.
- Levitra may cause nasal congestion or upset stomach.
- Combining vardenafil with other ED drugs increases risks.
- Alcohol can hinder the effectiveness of Levitra.
- Levitra is designed for occasional use, not daily.
- Precautions include monitoring for vision changes.
- Seek medical advice if you experience allergic reactions.
Tolterodine has been associated with dose-dependent prolongation of
| Brand Name | Active Ingredient | Medication Type | Typical Dosage | Available Forms |
|---|---|---|---|---|
| Levitra | Vardenafil | PDE5 Inhibitor | 5 mg, 10 mg, 20 mg | Tablets |
| Staxyn | Vardenafil ODT | PDE5 Inhibitor | 10 mg | Orally Disintegrating Tablets |
| Vidalista | Tadalafil (comparison) | PDE5 Inhibitor | 2.5 mg, 5 mg, 10 mg | Tablets |
the QT interval, especially in poor CYP2D6 metabolizers.
Authors' objectives
Also, coadministration of ribociclib with vardenafil should be avoided if possible due to an increased risk for QT prolongation. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. Vardenafil can produce QT prolongation at both therapeutic and supratherapeutic doses. Ribociclib; Letrozole: (Major) Concurrent use of vardenafil orally disintegrating tablets with ribociclib should be avoided due to increased vardenafil exposure. Rilpivirine: (Moderate) Concomitant use of vardenafil and rilpivirine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.
Storage and Handling
Riociguat: (Contraindicated) Use of riociguat and vardenafil is contraindicated due to the risk of hypotension. Discontinue riociguat at least 24 hours prior to vardenafil administration. Monitor for signs and symptoms of hypotension during transition of therapy. PDE5 inhibitors, including vardenafil, may potentiate the hypotensive effects of riociguat. Risperidone: (Moderate) Concomitant use of vardenafil and risperidone may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Therapeutic (10 mg) and supratherapeutic (80 mg) doses of vardenafil also produce an
Before Using
Promethazine; Phenylephrine: (Moderate) Concomitant use of promethazine and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Quetiapine: (Major) Concomitant use of vardenafil and quetiapine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Quinidine: (Major) Vardenafil should be avoided in patients taking Class IA antiarrhythmics (disopyramide, procainamide, and quinidine). Quinine: (Major) Concomitant use of vardenafil and quinine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Quizartinib: (Major) Concomitant use of quizartinib and vardenafil increases the risk of QT/QTc prolongation and torsade de pointes (TdP).
Participants included in the review
Ranolazine: (Major) Concomitant use of vardenafil and ranolazine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Relugolix: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., relugolix) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Relugolix; Estradiol; Norethindrone acetate: (Moderate) Concomitant use of vardenafil and androgen deprivation therapy (i.e., relugolix) may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Ribociclib: (Major) Concurrent use of vardenafil orally disintegrating tablets with ribociclib should be avoided due to increased vardenafil exposure. If use of vardenafil oral tablets and ribociclib is required, do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. increase in QTc interval (e.g., 4 to 6 msec calculated by individual QT correction).
- Levitra is available in 10 mg and 20 mg tablets.
- The medication is not an aphrodisiac; it enhances ability when sexually stimulated.
- Vardenafil is a PDE5 inhibitor class drug.
- It can be used by men with diabetes-related erectile issues.
- Levitra may cause dizziness; avoid driving after taking.
- The medication is approved by the FDA for ED treatment.
- Do not use if you have severe liver or kidney problems.
- Vardenafil should be stored at room temperature, away from moisture.
- It is not suitable for women or children.
- Consult your doctor for potential drug interactions.
- Levitra Dosage Options and Their Costco Pricing
- Vardenafil (Generic Equivalent of Levitra)
- Levitra free samples
- Important Safety Information and Contraindications
- Kamagra vs Viagra: Cost, Safety & Results Compared
- Cialis precio en farmacia españa
- Levitra γενοσημο τιμη φαρμακειου – Vardenafil αγορά με παράδοση στην Ελλάδα